{"name":"Natco Pharma","slug":"natco-pharma","ticker":"NATCOPHARM.NS","exchange":"NSE","domain":"natcopharma.co.in","description":"NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of i","hq":"Hyderabad, India","founded":0,"employees":"4199","ceo":"","sector":"Oncology Generics / Para IV / API","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":1204.4,"stockChange":32.5,"stockChangePercent":2.77,"marketCap":"$2.3B","metrics":{"revenue":476461999.84062463,"revenueGrowth":36.3,"grossMargin":82,"rdSpend":0,"netIncome":162614874.05464986,"cash":334617805.2769874,"dividendYield":0.55,"peRatio":13.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NRC-2694-A","genericName":"NRC-2694-A","slug":"nrc-2694-a","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"NRC-2694-A","genericName":"NRC-2694-A","slug":"nrc-2694-a","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":460693417.784,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":460693417.784},{"period":"2024-03-31","value":415497091.912},{"period":"2023-03-31","value":281631172.006},{"period":"2022-03-31","value":198924401.926}],"grossProfit":370332094.362,"grossProfitHistory":[{"period":"2025-03-31","value":370332094.362},{"period":"2024-03-31","value":325428166.162},{"period":"2023-03-31","value":203780291.836},{"period":"2022-03-31","value":127756897.116}],"rdSpend":11842105.716,"rdSpendHistory":[{"period":"2025-03-31","value":11842105.716},{"period":"2024-03-31","value":14797410.758},{"period":"2023-03-31","value":9419382.148},{"period":"2022-03-31","value":18473267.206}],"sgaSpend":28017962.642,"operatingIncome":206892238.488,"operatingIncomeHistory":[{"period":"2025-03-31","value":206892238.488},{"period":"2024-03-31","value":164661660.432},{"period":"2023-03-31","value":82508357.374},{"period":"2022-03-31","value":14703425.792}],"netIncome":196888060.996,"netIncomeHistory":[{"period":"2025-03-31","value":196888060.996},{"period":"2024-03-31","value":144977031.442},{"period":"2023-03-31","value":74697162.422},{"period":"2022-03-31","value":17752715.8}],"eps":105.26,"epsHistory":[{"period":"2025-03-31","value":105.26},{"period":"2024-03-31","value":77.34},{"period":"2023-03-31","value":39.18},{"period":"2022-03-31","value":9.32}],"cash":12531328.8,"cashHistory":[{"period":"2025-03-31","value":12531328.8},{"period":"2024-03-31","value":7351712.896},{"period":"2023-03-31","value":13774018.906},{"period":"2022-03-31","value":11601921.914}],"totalAssets":901294938.392,"totalLiabilities":106359653.19,"totalDebt":29177110.556,"equity":794381818.1800001,"operatingCashflow":177192989.232,"operatingCashflowHistory":[{"period":"2025-03-31","value":177192989.232},{"period":"2024-03-31","value":126524649.78400001},{"period":"2023-03-31","value":88669594.034},{"period":"2022-03-31","value":4855889.91}],"capex":-53425231.784,"capexHistory":[{"period":"2025-03-31","value":-53425231.784},{"period":"2024-03-31","value":-37458230.338},{"period":"2023-03-31","value":-21470343.344},{"period":"2022-03-31","value":-25344612.498}],"freeCashflow":123767757.448,"dividendsPaid":-11257310.372,"buybacks":0,"employees":4199,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":17815372.444000002,"ebitda":22639934.032,"period":"2025-12-31","revenue":67596076.102,"epsBasic":8.46,"netIncome":15820802.61,"rdExpense":null,"epsDiluted":8.46,"grossProfit":53696743.908,"operatingIncome":11748120.75},{"sga":null,"ebit":65455307.432000004,"ebitda":70927321.008,"period":"2025-09-30","revenue":142335009.62,"epsBasic":28.94,"netIncome":54135340.416,"rdExpense":null,"epsDiluted":28.94,"grossProfit":124613622.142,"operatingIncome":55012533.432000004},{"sga":null,"ebit":60056393.274000004,"ebitda":66071431.098,"period":"2025-06-30","revenue":138774023.686,"epsBasic":26.84,"netIncome":50198414.618,"rdExpense":null,"epsDiluted":26.84,"grossProfit":114442360.266,"operatingIncome":53613201.716},{"sga":null,"ebit":53174605.208000004,"ebitda":63439852.050000004,"period":"2025-03-31","revenue":125637013.994,"epsBasic":null,"netIncome":42460319.084,"rdExpense":null,"epsDiluted":null,"grossProfit":101482877.73200001,"operatingIncome":49101923.348},{"sga":null,"ebit":17554303.094,"ebitda":22462406.874,"period":"2024-12-31","revenue":49582290.952,"epsBasic":7.43,"netIncome":13888889.42,"rdExpense":null,"epsDiluted":7.43,"grossProfit":40935674.08,"operatingIncome":-856307.468},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":37.81,"netIncome":null,"rdExpense":null,"epsDiluted":37.81,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1204.4,"previousClose":1171.9,"fiftyTwoWeekHigh":1226.8,"fiftyTwoWeekLow":789,"fiftyTwoWeekRange":"789.0 - 1226.8","fiftyDayAverage":1052.94,"twoHundredDayAverage":911.94,"beta":0.26,"enterpriseValue":1945379704.8006737,"forwardPE":30.6,"priceToBook":2.49,"priceToSales":4.73,"enterpriseToRevenue":4.08,"enterpriseToEbitda":10.44,"pegRatio":0,"ebitda":186340867.27605045,"ebitdaMargin":39.1,"freeCashflow":0,"operatingCashflow":0,"totalDebt":27224312.486337535,"debtToEquity":3,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":10,"targetMeanPrice":938.1,"targetHighPrice":1180,"targetLowPrice":712,"dividendRate":6.5,"payoutRatio":0.06,"fiveYearAvgDividendYield":0.78,"exDividendDate":1771372800,"insiderHeldPercent":51,"institutionHeldPercent":11.6,"sharesOutstanding":179109870,"floatShares":83436028,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":86.95,"epsForward":39.36,"revenuePerShare":254.75,"bookValue":482.88,"officers":[{"age":80,"name":"Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS.","title":"MD & Chairman"},{"age":48,"name":"Mr. Rajeev  Nannapaneni","title":"CEO & Vice Chairman"},{"age":73,"name":"Dr. Donthineni Linga Rao M.D.","title":"President of Technical Affairs & Whole Time Director"},{"age":null,"name":"Mr. Chekuri Venkat Ramesh C.S.","title":"Company Secretary & Compliance Officer"},{"age":67,"name":"Mr. Potluri Sivaramakrishna Prasad","title":"Executive VP of Corporate Engineering Services & Whole Time Director"},{"age":null,"name":"Mr. Amit  Parekh","title":"CFO, Executive VP of Finance & Accounts"},{"age":null,"name":"Nadella Malleswara Rao","title":"VP & Head of Operations"},{"age":null,"name":"N. Sadasiva Rao","title":"Executive Vice President of Corporate Affairs, Legal, Secretarial & Estate Management"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.natcopharma.co.in","phone":"91 40 2354 7532"}}